<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03775993</url>
  </required_header>
  <id_info>
    <org_study_id>2016-004580-39</org_study_id>
    <nct_id>NCT03775993</nct_id>
  </id_info>
  <brief_title>Treatment of GHD Associated With CHF</brief_title>
  <official_title>Treatment of Growth Hormone Deficiency Associated With Chronic Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the current study is to assess the cardiovascular effects of GH replacement therapy in&#xD;
      patients with coexisting GHD and CHF&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple anabolic deficiencies are common in chronic heart failure (CHF) and identify&#xD;
      subgroups of patients with higher mortality. Apart from CHF, GH deficiency (GHD) per se&#xD;
      increases cardiovascular mortality in the general population and low IGF-1 levels in the&#xD;
      general population predict the development of ischemic heart disease and CHF. GHD modifies&#xD;
      cardiac size and function, through a reduction in both myocardial growth and cardiac&#xD;
      performance. The investigators therefore completed 2 studies aimed at evaluating the clinical&#xD;
      status, neurohormonal parameters, exercise capacity, vascular reactivity, and left&#xD;
      ventricular architecture and function in patients with GHD and CHF, at baseline and after 6&#xD;
      months of GH replacement therapy. They subsequently extended the observation period up to 48&#xD;
      months. At 6-months, GH replacement therapy improved clinical status and exercise capacity,&#xD;
      as shown by a significant reduction of the Minnesota living with heart failure questionnaire&#xD;
      score, increased peak oxygen consumption and exercise duration, and flow mediated&#xD;
      vasodilation of the brachial artery. No major adverse events were reported in the patients&#xD;
      receiving GH.&#xD;
&#xD;
      However, the encouraging results of these studies are limited by the lack of a double-blind,&#xD;
      placebo-controlled design, insofar as the investigators performed a randomized controlled,&#xD;
      single-blind study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of peak oxygen consumption (peak VO2)</measure>
    <time_frame>1 year</time_frame>
    <description>According to previous observations, the investigators set a target increase of peak VO2 in the treated arm at 3 ml/kg/min at the end of the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Hospitalizations</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End-systolic LV volumes</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP levels</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score from the Minnesota Living with Heart Failure Questionnaire</measure>
    <time_frame>1 year</time_frame>
    <description>The questionnaire is comprised of 21 physical, emotional and socioeconomic questions that may adversely affect a patient's life. After receiving brief standardized instructions, the patient marks a 0 (lower valure) to 5 (upper value) scale to indicate how much each itemized adverse of heart failure has prevented the patient from living as he or she wanted to live during the past 4 weeks. The final score is calculated by sum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Endothelial function (flow-mediated vasodilation)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength (handgrip)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the Levels of Endothelial Progenitor Cells (EPCs)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the Levels of lymphocyte G protein-coupled receptor kinase (GRK)-2</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Heart Failure</condition>
  <condition>Growth Hormone Deficiency</condition>
  <arm_group>
    <arm_group_label>GHD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human growth hormone</intervention_name>
    <description>Administration of growth hormone</description>
    <arm_group_label>GHD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration of placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. patients of either sex affected by CHF NYHA class I-III, secondary to ischemic or&#xD;
             idiopathic di-lated cardiomyopathy;&#xD;
&#xD;
          2. age range 18-85 years;&#xD;
&#xD;
          3. stable and optimal medical therapy for at least three months prior to randomization,&#xD;
             including ACE inhibitors or AT1 antagonists and beta-blockers (unless untolerated);&#xD;
&#xD;
          4. LV ejection fraction 40% or less and LV end-diastolic dimension 55 mm or more;&#xD;
&#xD;
          5. GH deficiency diagnosed with GHRH + arginine provocative test;&#xD;
&#xD;
          6. signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. inability to perform a bicycle exercise test;&#xD;
&#xD;
          2. poorly controlled diabetes mellitus (HbA1c &gt;8.5) and/or active proliferative or severe&#xD;
             non-proliferative diabetic retinopathy;&#xD;
&#xD;
          3. active and/or history of malignancy;&#xD;
&#xD;
          4. unstable angina or recent myocardial infarction (less than six months);&#xD;
&#xD;
          5. severe liver or kidney disease (serum creatinine levels &gt;2.5 mg/dl&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antonio Cittadini, Full Professor of Medicine</last_name>
    <phone>+390817464375</phone>
    <email>cittadin@unina.it</email>
  </overall_contact>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>December 12, 2018</study_first_submitted>
  <study_first_submitted_qc>December 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2018</study_first_posted>
  <last_update_submitted>February 13, 2019</last_update_submitted>
  <last_update_submitted_qc>February 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Antonio Cittadini</investigator_full_name>
    <investigator_title>Full Professor</investigator_title>
  </responsible_party>
  <keyword>Growth Hormone</keyword>
  <keyword>Placebo</keyword>
  <keyword>Exercise capacity</keyword>
  <keyword>Vascular reactivity</keyword>
  <keyword>LV function</keyword>
  <keyword>Prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dwarfism, Pituitary</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

